Disturbed adiponectin – AMPK system in skeletal muscle of patients with metabolic syndrome

Abstract

Patients with metabolic syndrome are characterized by low circulating adiponectin levels and reduced adiponectin sensitivity in skeletal muscles. Through binding on its main skeletal muscle receptor AdipoR1, adiponectin activates AMP-activated protein kinase (AMPK), a key player in energy homeostasis. Fourteen metabolic syndrome patients and seven healthy control subjects were included. Blood samples were taken to determine insulin resistance, adiponectin, lipoproteins, and C-reactive protein. Muscle biopsies (m. vastus lateralis) were obtained to assess mRNA expression of AdipoR1 and both AMPKα1 and AMPKα2 subunits, as well as downstream targets in lipid and glucose metabolism. Skeletal muscle mRNA expression of AMPKα1 and AMPKα2 was lower in metabolic syndrome patients (100 ± 6 vs. 122 ± 8 AU, p = 0.030 and 64 ± 4 vs. 85 ± 9 AU, p = 0.044, respectively), whereas the expression of AdipoR1 was upregulated (138 ± 9 vs. 105 ± 7, p = 0.012). AMPKα1 and AdipoR1 correlated positively in both the control (r = 0.964, p < 0.001) and the metabolic syndrome group (r = 0.600, p = 0.023). However, this relation was shifted upwards in metabolic syndrome patients, indicating increased AdipoR1mRNA expression for a similar AMPKα1 expression. Previously, a blunted stimulatory effect of adiponectin on AMPK activation has been shown in metabolic syndrome patients. The present data suggest that the disturbed interaction of adiponectin with AMPK is located downstream of the AdipoR1 receptor.

Keywords

Adiponectin AMPK metabolic syndrome skeletal muscle

Get full access to this article

View all access options for this article.

References

Kadowaki

Yamauchi

. Adiponectin and adiponectin receptors. Endocr Rev 2005; 26: 439–451.

Bluher

Bullen

Lee

. Circulating adiponectin and expression of adiponectin receptors in human skeletal muscle: associations with metabolic parameters and insulin resistance and regulation by physical training. J Clin Endocrinol Metab 2006; 91: 2310–2316.

Santaniemi M, Ukkola O, Malo E, et al. Metabolic syndrome in the prediction of cardiovascular events: the potential additive role of hsCRP and adiponectin. Eur J Prev Cardiol 2014; 21: 1242–1248.

Chen

McAinch

Macaulay

. Impaired activation of AMP-kinase and fatty acid oxidation by globular adiponectin in cultured human skeletal muscle of obese type 2 diabetics. J Clin Endocrinol Metab 2005; 90: 3665–3672.

Bruce

Mertz

Heigenhauser

. The stimulatory effect of globular adiponectin on insulin-stimulated glucose uptake and fatty acid oxidation is impaired in skeletal muscle from obese subjects. Diabetes 2005; 54: 3154–3160.

Tsuchida

Yamauchi

Ito

. Insulin/Foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity. J Biol Chem 2004; 279: 30817–30822.

Van Berendoncks

Garnier

Beckers

. Functional adiponectin resistance at the level of the skeletal muscle in mild to moderate chronic heart failure. Circ Heart Fail 2010; 3: 185–194.

Van Berendoncks

Conraads

Van Leuven

. Validation of an adiponectin immunoassay in human skeletal muscle biopsies. J Immunol Methods 2010; 362: 209–212.

Stensvold

Tjonna

Skaug

. Strength training vs. aerobic interval training to modify risk factors of metabolic syndrome. J Appl Physiol 2010; 108: 804–810.

10.

Wallace

Levy

Matthews

. Use and abuse of HOMA modeling. Diabetes Care 2004; 27: 1487–1495.